TAG / CLINICAL TRIAL
RESULTS
MENTAL HEALTH
FDA Rejects Ecstasy for Psychiatric Use, Prompting Drugmaker to Lay Off 75% of Staff
Almost 100 percent of trial participants reported adverse events using this dangerous hallucinogen.
